ICCC - ImmuCell Corporation

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
5.30
-0.20 (-3.64%)
As of 11:52AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close5.50
Open5.41
Bid5.30 x 1400
Ask5.68 x 1100
Day's Range5.30 - 5.43
52 Week Range4.70 - 8.44
Volume5,226
Avg. Volume6,206
Market Cap38.211M
Beta (3Y Monthly)0.64
PE Ratio (TTM)N/A
EPS (TTM)-0.30
Earnings DateMay 12, 2017 - May 15, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    ImmuCell Enters into Lease Agreement for a Facility to Expand First Defense® Production Capacity

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle – today announced that it has entered into a lease covering approximately 14,300 square feet of office and warehouse space effective approximately November 1, 2019.

  • GlobeNewswire

    ImmuCell Announces an Agreement Covering the Formulation and Aseptic Filling of Syringes for Re-Tain™

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle – today announced that it has entered into a new agreement with Norbrook Laboratories, Limited of Newry, Northern Ireland covering the formulation and aseptic filling of its Nisin Drug Substance into syringes for Re-Tain™, the Company’s novel treatment in development for subclinical mastitis in dairy cows. The new agreement (which replaces an expiring agreement) expires as of December 31, 2021 and allows for product ordered before the expiration date to be delivered into the early part of 2022.

  • Thomson Reuters StreetEvents

    Edited Transcript of ICCC earnings conference call or presentation 13-Aug-19 1:00pm GMT

    Q2 2019 ImmuCell Corp Earnings Call

  • GlobeNewswire

    ImmuCell Receives FDA Response To First CMC Submission for Re-Tain™

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle – today announced that it has received a response from the U.S. Food and Drug Administration (FDA) to its first phased Nisin Drug Substance submission of the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain™, the Company’s novel treatment in development for subclinical mastitis in lactating dairy cows.

  • GlobeNewswire

    ImmuCell Announces Unaudited Financial Results for Second Quarter of 2019

    PORTLAND, Maine, Aug. 12, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets.

  • Benzinga

    The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

    Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data integrity issues with Novartis AG (NYSE: NVS )'s regulatory ...

  • GlobeNewswire

    ImmuCell to Announce Unaudited Financial Results for Second Quarter of 2019

    PORTLAND, Maine, Aug. 06, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets.

  • Thomson Reuters StreetEvents

    Edited Transcript of ICCC earnings conference call or presentation 14-May-19 1:00pm GMT

    Q1 2019 ImmuCell Corp Earnings Call

  • Benzinga

    The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 13) BioSig Technologies Inc (NASDAQ: BSGM ) Milestone Pharmaceuticals ...

  • GlobeNewswire

    ImmuCell Announces Unaudited Financial Results for First Quarter of 2019

    PORTLAND, Maine, May 13, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets.

  • GlobeNewswire

    ImmuCell to Announce Unaudited Financial Results for First Quarter of 2019

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle - will report unaudited financial results for the quarter ended March 31, 2019 after the market closes on Monday, May 13, 2019.  The Company has scheduled a conference call the next day, Tuesday, May 14, 2019, at 9:00 AM ET to review the results. ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle.  ImmuCell markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef livestock, and is in the late stages of developing Re-Tain™, a novel treatment for mastitis, the most significant cause of economic loss to the dairy industry.  Press releases and other information about the Company are available at: http://www.immucell.com.

  • GlobeNewswire

    ImmuCell Corporation Announces Closing of $9 Million Public Offering of Common Stock

    ImmuCell Corporation (ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the closing of its previously announced underwritten public offering of 1,636,364 shares of common stock at a price to the public of $5.50 per share. All of the shares of common stock were offered by ImmuCell. The net proceeds from the offering are approximately $8.3 million, after deducting underwriting discounts and other estimated expenses incurred in connection with the offering.

  • GlobeNewswire

    ImmuCell Corporation Announces Pricing of $9.0 Million Public Offering of Common Stock

    ImmuCell Corporation (ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the pricing of its previously announced underwritten public offering of 1,636,364 shares of common stock of the Company at a price to the public of $5.50 per share. ImmuCell expects to receive aggregate gross proceeds of approximately $9.0 million from the offering.  All of the shares of common stock are being offered by ImmuCell.  The offering is expected to close on or about March 29, 2019, subject to customary closing conditions. Craig-Hallum Capital Group is acting as sole managing underwriter for the offering.

  • GlobeNewswire

    ImmuCell Corporation Announces Commencement of Public Offering of Common Stock

    ImmuCell Corporation (ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock are being offered by ImmuCell. Craig-Hallum Capital Group is acting as sole managing underwriter for the offering.

  • GuruFocus.com

    ImmuCell Corp (ICCC) Files 10-K for the Fiscal Year Ended on December 31, 2018

    ImmuCell Corp is engaged in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. ImmuCell Corp had annual average EBITDA growth of 5.30% over the past five years. Warning! GuruFocus has detected 6 Warning Signs with ICCC.

  • Do Directors Own ImmuCell Corporation (NASDAQ:ICCC) Shares?
    Simply Wall St.

    Do Directors Own ImmuCell Corporation (NASDAQ:ICCC) Shares?

    If you want to know who really controls ImmuCell Corporation (NASDAQ:ICCC), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders,Read More...

  • GlobeNewswire

    ImmuCell Announces Submission of Manufacturing Technical Section for its Purified Nisin Product

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a critical milestone in the development of Re-Tain™, its Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The Company has made its first phased submission to the U.S. Food and Drug Administration (FDA) of the manufacturing technical section (known as the Chemistry, Manufacturing and Controls (CMC) Technical Section) with respect to the Nisin Drug Substance under the Company’s New Animal Drug Application (NADA).  This submission is subject to a six-month review period and will be followed by a second phased submission covering the Nisin Drug Product, which is also subject to a six-month review period before anticipated product approval can occur.

  • Benzinga

    The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 13) Abbott Laboratories (NYSE: ABT ) Ionis Pharmaceuticals ...

  • GlobeNewswire

    ImmuCell Announces Preliminary Financial Results for Fourth Quarter and Full Year 2018

    PORTLAND, Maine, Feb. 13, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets.

  • GlobeNewswire

    ImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2018

    PORTLAND, Maine, Feb. 06, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets.

  • Thomson Reuters StreetEvents

    Edited Transcript of ICCC earnings conference call or presentation 14-Nov-18 2:00pm GMT

    Q3 2018 ImmuCell Corp Earnings Call

  • GlobeNewswire

    ImmuCell Announces USDA Approval of Dual-Force™ First Defense®

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that the USDA has issued a product license for Dual-Force™ First Defense®. The gel tube delivery format is a preferred administration route for some, as an alternative to the Company’s longstanding First Defense® capsule. “Our goal is to formulate our efficacious colostrum antibodies into a variety of formats so that our customers can choose the option that works best for their operations,” commented Michael F. Brigham, President and CEO.

  • GlobeNewswire

    Report: Developing Opportunities within ReWalk Robotics, ImmuCell, SCYNEXIS, Fuel Tech, Garrison Capital, and AMREP — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire

    ImmuCell Announces Financial Results for Third Quarter of 2018

    PORTLAND, Maine, Nov. 13, 2018 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets.

  • GlobeNewswire

    ImmuCell to Participate at 9th Annual Craig-Hallum Alpha Select Conference

    PORTLAND, Maine, Nov. 08, 2018 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets.